Jean-Guy Rolland
Research Subjects
Research Interests
Jean-Guy Rolland has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Agnès Perrin-Guyomard
ANSES-Fougères Laboratory (French National Agency for Food, Environment and Occupational Health & Safety), 10 B, rue Claude Bourgelat - Javené, CS 40608, 35306 CEDEX Fougères, France
1 shared publication - Jacqueline Manceau
ANSES, Fougères Laboratory, Scientific Support Unit, 10B rue Claude Bourgelat, Javené, CS 40608, Fougères 35306, France
1 shared publication - Jean-Michel Delmas
Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 35306 Fougères CEDEX, France
1 shared publication - Manuel Jimmy Saint-Cyr
ANSES, Fougères Laboratory, Antibiotics, Biocides, Residues and Resistance Unit, 10B rue Claude Bourgelat, Javené, CS 40608, Fougères 35306, France
1 shared publication - Michel Laurentie
Agence Nationale de Sécurité Sanitaire, French Agency for Food, Environmental and Occupational Health Safety, Platform PAS, Laboratory of Fougères, 10 Bis rue Claude Bourgelat, Javené, France
1 shared publication - Paméla Houée
Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 35300 Fougères, France
1 shared publication
Latest Publications
- Open Access
Risk Assessment of Deoxynivalenol by Revisiting Its Bioavailability in Pig and Rat Models to Establish Which Is More Suitable
Due to its toxic properties, high stability, and prevalence, the presence of deoxynivalenol (DON) in the food chain is a major threat to food safety and therefore a health risk for both humans and animals. In this study, experiments were carried out with sows and female rats to examine the kinetics of DON after intravenous and oral administration at 100 µg/kg of body weight. After intravenous administration of DON in pigs, a two-compartment model with rapid initial distribution (0.030 ± 0.019 h) followed by a slower terminal elimination phase (1.53 ± 0.54 h) was fitted to the concentration profile of DON in pig plasma. In rats, a short elimination half-life (0.46 h) and a clearance of 2.59 L/h/kg were estimated by sparse sampling non-compartmental analysis. Following oral exposure, DON was rapidly absorbed and reached maximal plasma concentrations (Cmax) of 42.07 ± 8.48 and 10.44 ± 5.87 µg/L plasma after (tmax) 1.44 ± 0.52 and 0.17 h in pigs and rats, respectively. The mean bioavailability of DON was 70.5% ± 25.6% for pigs and 47.3% for rats. In the framework of DON risk assessment, these two animal models could be useful in an exposure scenario in two different ways because of their different bioavailability.
Open AccessRisk Assessment of Deoxynivalenol by Revisiting Its Bioavailability in Pig and Rat Models to Establish Which Is More Suitable
Due to its toxic properties, high stability, and prevalence, the presence of deoxynivalenol (DON) in the food chain is a major threat to food safety and therefore a health risk for both humans and animals. In this study, experiments were carried out with sows and female rats to examine the kinetics of DON after intravenous and oral administration at 100 µg/kg of body weight. After intravenous administration of DON in pigs, a two-compartment model with rapid initial distribution (0.030 ± 0.019 h) followed by a slower terminal elimination phase (1.53 ± 0.54 h) was fitted to the concentration profile of DON in pig plasma. In rats, a short elimination half-life (0.46 h) and a clearance of 2.59 L/h/kg were estimated by sparse sampling non-compartmental analysis. Following oral exposure, DON was rapidly absorbed and reached maximal plasma concentrations (Cmax) of 42.07 ± 8.48 and 10.44 ± 5.87 µg/L plasma after (tmax) 1.44 ± 0.52 and 0.17 h in pigs and rats, respectively. The mean bioavailability of DON was 70.5% ± 25.6% for pigs and 47.3% for rats. In the framework of DON risk assessment, these two animal models could be useful in an exposure scenario in two different ways because of their different bioavailability.